摘要
近年来,基于α粒子的核素靶向治疗在肿瘤临床前及临床研究中显示出了非常大的潜力。225Ac可用于放射性核素靶向治疗,国内外已开展多项临床前研究及临床研究,并取得了一定成果。该文对225Ac的治疗特性及其在目前研究较多的几种恶性肿瘤中的现状进行概述,并分析225Ac用于核素靶向治疗面临的问题与挑战。
In recent years,the application of alpha particle-based nuclide targeted therapy in tumors has shown great potential.225Ac is a nuclide that can be used for alpha radionuclide targeted therapy which has been studied at home and abroad.A number of preclinical and clinical trials have been carried out,and some achievements have been obtained.This article summarizes the current research status of several malignant tumors,and analyzes the challenges and progress faced by 225Ac in radionuclide targeted therapy.
作者
马佼
欧蕾
饶梓娟
廖太平
李兰英
张春银
Ma Jiao;Ou Lei;Rao Zijuan;Liao Taiping;Li Lanying;Zhang Chunyin(Department of Nuclear Medicine,the Affiliated Hospital of Southwest Medical University Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province Academician(Expert)Workstation of Sichuan Province,Luzhou 646000,China)
出处
《中华核医学与分子影像杂志》
CAS
CSCD
北大核心
2023年第1期52-54,共3页
Chinese Journal of Nuclear Medicine and Molecular Imaging
作者简介
通信作者:张春银,Email:zhangchunyin345@sina.com。
